Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCPMP/EWP/2339/02
Effective from01/08/2005
KeywordsPharmacokinetics, physiologically based pharmacokinetic modelling (PBPK), hepatic impairment, impaired hepatic function, liver, Child-Pugh classification, population pharmacokinetics, summary of product characteristics
DescriptionThis document gives recommendation on situations when pharmacokinetic studies should be performed in subjects with impaired hepatic funtion. It provides guidance on the design of such studies as well as data presentation, analysis, evaluation of results and reflection of those results in the summary of product characteristics.

Related content

How helpful is this page?

Average rating:

 Based on 30 ratings

Add your rating:

See all ratings
6 ratings
6 ratings
6 ratings
6 ratings
6 ratings

Tell us more